Evidence map›Paper›PMID 36994921›Full record

ArticleBiomaterials science2023

Single-tailed heterocyclic carboxamide lipids for macrophage immune-modulation.

Kuo-Ching Mei, Rebeca T Stiepel, Emily Bonacquisti, Natalie E Jasiewicz, Ameya Pravin Chaudhari, Palas B Tiwade, Eric M Bachelder, Kristy M Ainslie, Owen S Fenton, Juliane Nguyen

Abstract read
In one paragraph

Article in Biomaterials science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kuo-Ching MeiDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.ORCID http://orcid.org/0000-0001-6045-2154
Rebeca T StiepelDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Emily BonacquistiDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Natalie E JasiewiczDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Ameya Pravin ChaudhariDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Palas B TiwadeDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Eric M BachelderDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Kristy M AinslieDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.ORCID http://orcid.org/0000-0002-1820-8382
Owen S FentonDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.
Juliane NguyenDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 29599, USA. julianen@email.unc.edu.ORCID http://orcid.org/0000-0002-8578-7396

Funding

Optimizing a Universal Influenza Subunit Nano/Microparticulate VaccineR01AI147497 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AINSLIE, KRISTY M · 2020 to 2024
$2.9M
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor EpitopesR01CA241679 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2020 to 2024
$1.9M
Engineering a cross-linked cellular network for cardiac repairR01HL161456 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2022 to 2025
$1.9M
Antibody Fragments as Biochemical Tools to Interrogate CD9 Function in Inflammatory DiseasesR21GM135853 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE, WOHLFERT, ELIZABETH · 2020 to 2021
$433k
NCI NIH HHS R01 CA241679NHLBI NIH HHS R01 HL161456NIAID NIH HHS R01 AI147497NIGMS NIH HHS R21 GM135853
6 · The paper itself

Abstract

The discovery of new immune-modulating biomaterials is of significant value to immuno-engineering and therapy development. Here, we discovered that single-tailed heterocyclic carboxamide lipids preferentially modulated macrophages - but not dendritic cells - by interfering with sphingosine-1-phosphate-related pathways, consequently increasing interferon alpha expression. We further performed extensive downstream correlation analysis and determined key factors in physicochemical properties likely to modulate pro-inflammatory and anti-inflammatory immune responses. These properties will be useful for the rational design of the next generation of cell type-specific immune-modulating lipids.

Indexed as

Biocompatible MaterialsMacrophagesImmunityLipidsBiocompatible MaterialsLipids

Identifiers

PMID36994921
PMCPMC10388338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.